<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Luxturna_Initial_COVERAGE_CRITERIA_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Initiation criteria
1. Patients who have all of the following characteristics:
1.1. biallelic RPE65 mutations, as confirmed by an accredited laboratory using validated assay methods.
1.2. possess sufficient viable retinal cells, as determined by an inherited retinal disease specialist.
1.3. are at least four years of age.
1.4. visual acuity worse than 20/60 (both eyes) and/or visual field less than 20 degrees in any meridian as measured by III4e isopter or
equivalent (both eyes).
Prescribing Conditions
1. Treatment should be limited to one treatment per eye per patient lifetime.
2. Patient selection and the pre- and post-surgical evaluations should be carried out by a physician who specializes in inherited retinal
diseases.
3. Treatment with voretigene neparvovec should be administered by a retinal surgeon experienced in performing submacular injection
and management of associated complications.</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>Luxturna_Initial_COVERAGE_CRITERIA_Q1</developerName>
    <name>Luxturna_Initial_COVERAGE_CRITERIA_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
